JP2015515462A5 - - Google Patents

Download PDF

Info

Publication number
JP2015515462A5
JP2015515462A5 JP2015501731A JP2015501731A JP2015515462A5 JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5 JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5
Authority
JP
Japan
Prior art keywords
blood
pegylated
composition
subject
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015501731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515462A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/030355 external-priority patent/WO2013142135A1/en
Publication of JP2015515462A publication Critical patent/JP2015515462A/ja
Publication of JP2015515462A5 publication Critical patent/JP2015515462A5/ja
Pending legal-status Critical Current

Links

JP2015501731A 2012-03-20 2013-03-12 輸血の有効性を高める方法 Pending JP2015515462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613105P 2012-03-20 2012-03-20
US61/613,105 2012-03-20
PCT/US2013/030355 WO2013142135A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Publications (2)

Publication Number Publication Date
JP2015515462A JP2015515462A (ja) 2015-05-28
JP2015515462A5 true JP2015515462A5 (https=) 2016-04-21

Family

ID=49223191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501731A Pending JP2015515462A (ja) 2012-03-20 2013-03-12 輸血の有効性を高める方法

Country Status (10)

Country Link
US (2) US8859499B2 (https=)
EP (1) EP2827887A4 (https=)
JP (1) JP2015515462A (https=)
BR (1) BR112014023200A2 (https=)
CL (1) CL2014002464A1 (https=)
HK (1) HK1204267A1 (https=)
IN (1) IN2014MN02089A (https=)
MX (1) MX2014011186A (https=)
WO (1) WO2013142135A1 (https=)
ZA (1) ZA201407616B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
IN2014MN02089A (https=) 2012-03-20 2015-09-11 Einstein Coll Med
NZ720949A (en) * 2013-12-09 2019-03-29 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
US20170333566A1 (en) * 2014-11-14 2017-11-23 Aima Biotech Conjugated Proteins
ES2774365T3 (es) 2014-11-25 2020-07-20 Curadigm Sas Composición farmacéutica, preparación y usos de la misma
EP3096160B1 (en) * 2015-05-20 2020-02-26 Veoneer Sweden AB An fmcw vehicle radar system
UA124572C2 (uk) 2015-05-28 2021-10-13 Нанобіотікс Наночастинки для застосування як терапевтичної вакцини
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US11065277B2 (en) * 2015-11-09 2021-07-20 Albert Einstein College Of Medicine Method of ameliorating side effects of sickle cell disease treatments
WO2017103914A1 (en) * 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
EP3995141B1 (en) 2016-04-28 2024-01-03 Alkahest, Inc. Plasma fractions as therapy for thymic cancer
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MX2019012795A (es) 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CA3070172A1 (en) 2017-07-18 2019-01-24 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
JP7773169B2 (ja) * 2021-02-24 2025-11-19 学校法人 中央大学 ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
JPS56139419A (en) * 1980-03-31 1981-10-30 Kuraray Co Ltd Erythrocytic preservative and erythrocytic pharmaceutical for preservation
CA2320156A1 (en) * 1997-09-26 1999-04-08 Uab Research Foundation Reduced antigenic cells and uses therefor
WO2000018418A2 (en) * 1998-09-25 2000-04-06 Oklahoma Medical Research Foundation Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US6875423B1 (en) * 1999-09-21 2005-04-05 Marcos Intaglietta Methods for increasing peripheral blood circulation
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
US6811778B2 (en) * 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
KR20070094754A (ko) * 2004-12-01 2007-09-21 데브젠 엔브이 이온 채널, 특히 Kv 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체
WO2007058678A2 (en) * 2005-06-10 2007-05-24 Albert Einstein College Of Medicine Of Yeshiva University Uses of pegylated albumin
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
CN102300555B (zh) * 2009-01-30 2015-06-17 卡斯伯特·O·辛普金斯 复苏液
WO2010117423A2 (en) * 2009-03-31 2010-10-14 Duke University A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
NO2440239T3 (https=) * 2009-06-09 2018-02-10
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
US20130231287A1 (en) * 2010-02-25 2013-09-05 Parimala Nacharaju Pegylated albumin polymers and uses thereof
IN2014MN02089A (https=) 2012-03-20 2015-09-11 Einstein Coll Med
US20170333566A1 (en) 2014-11-14 2017-11-23 Aima Biotech Conjugated Proteins

Similar Documents

Publication Publication Date Title
JP2015515462A5 (https=)
Li et al. Scaffold-facilitated locomotor improvement post complete spinal cord injury: Motor axon regeneration versus endogenous neuronal relay formation
JP2014520142A5 (https=)
IL294463A (en) Methods for treating or preventing eye conditions
CN102406205B (zh) 牡蛎多糖果汁饮料
JP2017532343A5 (https=)
TR201909355T4 (tr) Oral uygulama için proton bağlayıcı polimerler.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
JP2012528890A5 (https=)
Lieder et al. Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes
RU2018123666A (ru) Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина
JP2017522288A5 (https=)
Kelly et al. TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia
JP2016513523A5 (https=)
CN105400214A (zh) 一种使用透明质酸交联明胶制备止血棉的方法
Ali et al. HORMONAL INDUCTION OF OVARIAN CYCLICITY AND CONCEPTION RATE IN POSTPARTUM ANESTRUS BUFFALOES.
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2017525704A5 (https=)
Schmidt et al. Remote ischemic conditioning: the cardiologist's perspective
JP2005511504A5 (https=)
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES
WO2012075244A3 (en) Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
CN103301451B (zh) 一种皮内注射用布氏菌活疫苗冻干保护剂
CN108367023B (zh) 预防宿主中移植物衰竭的方法
RU2017115859A (ru) Офтальмологические композиции